HemoGenyx Pharmaceuticals Plc (HOPHF)
2.33
0.00 (0.00%)
USD |
OTCM |
Sep 04, 16:00
HemoGenyx Pharmaceuticals SG&A Expense (TTM) : 8.463M for Dec. 31, 2025
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2025 | 8.463M |
| June 30, 2025 | 5.993M |
| December 31, 2024 | 6.054M |
| June 30, 2024 | 5.408M |
| December 31, 2023 | 7.215M |
| June 30, 2023 | 7.532M |
| December 31, 2022 | 4.167M |
| June 30, 2022 | 3.453M |
| Date | Value |
|---|---|
| December 31, 2021 | 3.539M |
| June 30, 2021 | 3.071M |
| December 31, 2020 | 2.628M |
| June 30, 2020 | 2.129M |
| December 31, 2019 | 2.027M |
| June 30, 2019 | 2.081M |
| December 31, 2018 | 2.082M |
| June 30, 2018 | 0.9838M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Silence Therapeutics Plc | 21.27M |
| Biodexa Pharmaceuticals Plc | 6.375M |
| NuCana Plc | 7.064M |
| Mereo BioPharma Group Plc | 19.44M |
| Compass Pathways Plc | 68.79M |